Share
Ignoring natural immunity and the very low risk to children
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
 
Hi Friend,
In Wednesday's newsletter, I introduced how the FDA brazenly perpetrated outright scientific fraud in its emergency use authorization of Pfizer's COVID-19 vaccine for infants and toddlers. If you missed that email, you can read it online here.

As I mentioned, in anticipation of a major paper I'll be publishing, the next series of newsletters I'll be sending, starting with this one, will summarize how the FDA exaggerates the risks posed to infants and toddlers from COVID-19.

The first key point is that for its risk-benefit analysis, the FDA willfully ignored natural immunity and downplayed the very low risk to children from SARS-CoV-2, the coronavirus that causes COVID-19.

The FDA claimed that a cumulative total of 202 children aged six months to four years had died from COVID-19 in the US as of May 11. The FDA highlighted these deaths as a reason to vaccinate children.

However, the FDA willfully withheld the fact that the infection fatality rate among children is statistically zero. Recently published data from the UK show that the fatality rate among children and adolescents is 0.0007%. That's one death per 142,857 infections.

To substantiate or falsify its assumption that vaccination of very young children will reduce the risk of dying from COVID-19, the clinical trials would therefore had to have included hundreds of thousands of children. Instead, the FDA based its decision on efficacy data failing to show a significant benefit from a trial population of just 4,526 children aged six months to four years old, among whom 3,013 were assigned to receive the vaccine.

Moreover, the dataset the FDA cited is not limited to deaths for which COVID-19 was listed as the underlying cause on death certificates. Rather, the data includes all deaths "involving" COVID-19, regardless of whether it was listed as the underlying cause (bottom line of Part I) or as a possible contributing factor (Part II) on the death certificate. Just because someone dies after testing positive for SARS-CoV-2 RNA does not mean that they died because of COVID-19.

The same study from the UK I just mentioned also importantly found that precisely this type of practice overestimates deaths due to COVID-19. The research team carefully reviewed death registrations and contacted clinicians as necessary to exclude deaths for which COVID-19 was clearly not the cause.

The FDA failed to do that, and it misled by describing those 202 deaths as having been caused by COVID-19 when the accurate description would be "COVID-19-associated deaths", which is inclusive of deaths for which a positive SARS-CoV-2 test was incidental.

Finally, a seroprevalence study by CDC researchers estimated that 75% of children in the US have already experienced SARS-CoV-2 infection. Consequently, 75% of children have evidence of natural immunity.

This is likely an underestimate since they used a test to detect antibodies against the nucleocapsid (N) protein of the virus. Since anti-N antibodies wane over time, a certain proportion of children were likely to have tested negative despite having acquired natural immunity. Additionally, many children had already been vaccinated, and it is known that previously uninfected vaccinated individuals have an impaired ability to produce anti-N antibodies.

Thus, according to the government's own data, most children in the US have already acquired natural immunity, yet the FDA conducted its risk-benefit analysis as though all children were immunologically naïve.

The FDA explicitly acknowledges this "limitation" of its analysis, noting that it did not assess the benefit of vaccination in "previously infected" children.

The FDA certainly knows that to conduct a risk-benefit analysis on the basis of an already falsified assumption that an unvaccinated child is an immunologically naïve child is scientifically fraudulent, but that's what the FDA did anyway.

In my next newsletter, I'll explain how the FDA lied about risk factors for COVID-19 hospitalization among young children.
So far this month, 65 readers have contributed a total of $2,697, bringing me 45% of the way toward my minimum fundraiser goal for July. That's awesome because on Wednesday, I was at only 9% goal progress! So, a big thanks to everyone who generously chipped in!
If you appreciate the work that I do and would like to contribute, it is easy to make a one-time or recurring donation using the form on my crowdfunding page (which is an advanced new system that replaced the simple PayPal buttons I used to use). If you'd like to set up a recurring donation, you can select the interval.

Payment options include credit card (via Stripe gateway), Zelle (no fees!), and check. (PayPal is also an option, but there is evidently a bug preventing login right now that I'll need to troubleshoot and fix -- sorry!) I can also accept Bitcoin via Strike.

You can also choose whether to give anonymously or be recognized for your contribution (you'll see a donor wall on my crowdfunding page).

If it's not in your budget to provide financial support, you can also help me out a lot by taking a moment to leave a reader testimonial. This type of "social proof" of the value of my work helps me establish the perceived credibility and authority needed to reach new audiences. You can read what others have had to say and share your own thoughts using the testimonial form at the bottom of my crowdfunding page:
In Solidarity,
Jeremy R. Hammond
Independent Journalist and Author

JeremyRHammond.com
 
Follow Me on Social Media
 
You are receiving this email because you signed up for my newsletter on my website.

Want to update your subscription profile?
Click here to update your info.

No longer want to receive my emails?


Jeremy R. Hammond
P.O. Box 76
Petoskey, Michigan 49770
United States



Email Marketing by ActiveCampaign